Status: Recruiting
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
This study is an open-label Phase II randomized controlled trial designed to evaluate the safety and efficacy of camrelizumab plus fluzoparib maintenance therapy in patients with recurrent or metastatic TP-53 mutated Endometrial Cancer. The study will also explore the prevalence of homologous recombination reficiency in Chinese patients with TP-53 mutated endometrial cancer and its therapeutic significance.
Participants needed: 117
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Cancer Institute and Hospital, Chinese Academy of Medical SciencesUpdated: May 14, 2024Locations: 1
Eligibility criteria
Age ≥18 [+10]
Currently participating in another clinical trial or within 4 weeks since comple... [+16]